Jun 2026 (Q2 FY26) — Aug 5, 2026
BioVentus Q2 FY26 — Strong Performance Across Business, Strategic Review Initiated
Read the full callBioVentus (BVS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
BioVentus earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 153 | +3.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 12.5 | +0.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 33.4 | +348.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$13.49 +1.43% · +$0.19
Performance +102.6% 1Y
1Y: $6.66 on 17 Oct 2025 → $13.49. High $15.26 (5 Aug 2026), low $6.53 (20 Nov 2025).
- Previous close
- $13.3
- 52-week range
- $6.53 – $15.26
- One year
- +92.71%
Overview
- Symbol
- BVS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
BioVentus earnings calls (BVS)
Financials
What the filings say
Net profit, year on year: +348% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 139 | 154 | 124 | 148 | 139 | 158 | 132 | 153 |
| Operating profit | 4 | 8 | 5 | 18 | 11 | 19 | 8 | 19 |
| Operating margin | 2.6% | 5.2% | 3.9% | 12.4% | 8.1% | 12.3% | 6.4% | 12.5% |
| Other income | -9 | -8 | -8 | -8 | -7 | -5 | -4 | -4 |
| Profit before tax | -5 | 0 | -3 | 10 | 5 | 14 | 5 | 15 |
| Tax rate | −11.2% | 237.1% | 2.8% | 10.1% | 14.2% | −22.4% | 12.6% | −136.5% |
| Net profit | -5 | -0 | -3 | 7 | 3 | 15 | 3 | 33 |
| EPS ($ per share) | -0.08 | — | -0.04 | 0.11 | 0.05 | — | 0.05 | 0.49 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Reserves | — | -7 | -165 | -322 | -358 | -335 |
| Total liabilities | 350 | 618 | 960 | 590 | 542 | 455 |
| Fixed assets | 7 | 23 | 28 | 37 | 27 | 22 |
| Total assets | 494 | 1,226 | 1,373 | 811 | 728 | 684 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 41 | 72 | 23 | -14 | 15 | 39 | 75 |
| Cash from investing | -8 | -20 | -284 | -116 | 16 | 23 | -3 |
| Cash from financing | -11 | -30 | 273 | 62 | -27 | -55 | -62 |
| Net cash flow | 22 | 22 | 12 | -67 | 5 | 5 | 10 |
| Capital expenditure | -2 | -17 | -14 | -1 | -7 | -1 | -3 |
| Free cash flow | 38 | 55 | 9 | -15 | 8 | 38 | 72 |
Insider filings
41 filings between Nov 7, 2025 and Jun 2, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$312.4K
3 sales by 2 insiders
Compensation
not trading decisions- 24
- Option exercise — converted options into shares
- 14
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| McMurry-Heath Michelle | — | $236.7K | Mar 11, 2026 |
| NOHRA GUY P | — | $75.7K | Dec 4, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 2, 2026 | NEELS GUIDO J Director | Option exercise | 32,282 | $0 |
| Jun 2, 2026 | Bartholdson John A. Director | Option exercise | 32,282 | $0 |
| Jun 2, 2026 | Beyer Pat Director | Option exercise | 32,282 | $0 |
| Jun 2, 2026 | Cowdy Philip G. Director | Option exercise | 32,282 | $0 |
| Jun 2, 2026 | Ladone Mary Kay Director | Option exercise | 32,282 | $0 |
| Jun 2, 2026 | McMurry-Heath Michelle Director | Option exercise | 32,282 | $0 |
| Jun 2, 2026 | SUTTER MARTIN P Director | Option exercise | 32,282 | $0 |
| Jun 2, 2026 | HAWKINS WILLIAM A Director | Option exercise | 39,789 | $0 |
| Jun 2, 2026 | NOHRA GUY P Director | Option exercise | 32,282 | $0 |
| Jun 2, 2026 | STALNECKER SUSAN M Director | Option exercise | 32,282 | $0 |
| Apr 10, 2026 | CHURCH KATRINA J SVP & Chief Compliance Officer | Option exercise | 4,300 | $0 |
| Apr 10, 2026 | CHURCH KATRINA J SVP & Chief Compliance Officer | Tax withheld | 1,868 | $16.9K |
| Apr 10, 2026 | D'Adamio Anthony SVP & General Counsel | Option exercise | 9,925 | $0 |
| Apr 10, 2026 | D'Adamio Anthony SVP & General Counsel | Tax withheld | 4,312 | $39.1K |
| Apr 10, 2026 | Singleton Mark Leonard SVP & CFO | Option exercise | 13,000 | $0 |
| Apr 10, 2026 | Singleton Mark Leonard SVP & CFO | Tax withheld | 5,648 | $51.2K |
| Mar 20, 2026 | Singleton Mark Leonard SVP & CFO | Option exercise | 18,625 | $0 |
| Mar 20, 2026 | Singleton Mark Leonard SVP & CFO | Tax withheld | 8,091 | $69.9K |
| Mar 13, 2026 | CHURCH KATRINA J SVP & Chief Compliance Officer | Option exercise | 3,455 | $0 |
| Mar 13, 2026 | CHURCH KATRINA J SVP & Chief Compliance Officer | Tax withheld | 1,501 | $12.9K |
| Mar 13, 2026 | CHURCH KATRINA J SVP & Chief Compliance Officer | Option exercise | 3,500 | $0 |
| Mar 13, 2026 | CHURCH KATRINA J SVP & Chief Compliance Officer | Tax withheld | 1,521 | $13.1K |
| Mar 13, 2026 | D'Adamio Anthony SVP & General Counsel | Option exercise | 8,886 | $0 |
| Mar 13, 2026 | D'Adamio Anthony SVP & General Counsel | Tax withheld | 3,861 | $33.3K |
| Mar 13, 2026 | D'Adamio Anthony SVP & General Counsel | Option exercise | 8,750 | $0 |
| Mar 13, 2026 | D'Adamio Anthony SVP & General Counsel | Tax withheld | 3,802 | $32.8K |
| Mar 13, 2026 | Singleton Mark Leonard SVP & CFO | Option exercise | 13,500 | $0 |
| Mar 13, 2026 | Singleton Mark Leonard SVP & CFO | Tax withheld | 5,865 | $50.6K |
| Mar 13, 2026 | Claypoole Robert E President and CEO | Option exercise | 33,500 | $0 |
| Mar 13, 2026 | Claypoole Robert E President and CEO | Tax withheld | 14,553 | $125.4K |
| Mar 11, 2026 | McMurry-Heath Michelle Director | Sale | 12,000 | $105.4K |
| Feb 15, 2026 | CHURCH KATRINA J SVP & Chief Compliance Officer | Option exercise | 4,375 | $0 |
| Feb 15, 2026 | CHURCH KATRINA J SVP & Chief Compliance Officer | Tax withheld | 2,133 | $17.6K |
| Feb 15, 2026 | D'Adamio Anthony SVP & General Counsel | Option exercise | 12,980 | $0 |
| Feb 15, 2026 | D'Adamio Anthony SVP & General Counsel | Tax withheld | 6,327 | $52.3K |
| Feb 15, 2026 | Singleton Mark Leonard SVP & CFO | Option exercise | 20,153 | $0 |
| Feb 15, 2026 | Singleton Mark Leonard SVP & CFO | Tax withheld | 9,429 | $78.0K |
| Jan 9, 2026 | Claypoole Robert E President and CEO | Option exercise | 93,750 | $0 |
| Jan 9, 2026 | Claypoole Robert E President and CEO | Tax withheld | 41,717 | $335.0K |
| Dec 4, 2025 | NOHRA GUY P Director | Sale | 10,000 | $75.7K |
| Nov 7, 2025 | McMurry-Heath Michelle Director | Sale | 17,701 | $131.3K |
| Jun 6, 2025 | Bartholdson John A. Director | Option exercise | 7,575 | $0 |
| Jun 2, 2025 | Bartholdson John A. Director | Option exercise | 26,493 | $0 |
| Jun 2, 2025 | NOHRA GUY P Director | Option exercise | 26,493 | $0 |
| Jun 2, 2025 | STALNECKER SUSAN M Director | Option exercise | 26,493 | $0 |
| Jun 2, 2025 | SUTTER MARTIN P Director | Option exercise | 26,493 | $0 |
| Jun 2, 2025 | Beyer Pat Director | Option exercise | 26,493 | $0 |
| Jun 2, 2025 | HAWKINS WILLIAM A Director | Option exercise | 26,493 | $0 |
| Jun 2, 2025 | Ladone Mary Kay Director | Option exercise | 26,493 | $0 |
| Jun 2, 2025 | McMurry-Heath Michelle Director | Option exercise | 26,493 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Bioventus Inc.
Free account. Everything above stays public.
Write why you follow Bioventus Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading